Overview

Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin

Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Pasireotide
Somatostatin